NCT00478218 - Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

September 30, 2008

Study Completion Date

April 30, 2011

Conditions

Multiple Myeloma and Plasma Cell Neoplasm

Interventions

DRUG

cyclophosphamide

300 mg/m2 administrated by PO (with food)on Days 1, 8, 15 (up to 12 cycles) OR 300 mg administrated by PO (with food)on Days 1, 8, 15 (up to 12 cycles)

DRUG

dexamethasone

40 mg administrated by PO (with food)on Days 1, 8, 15 \& 22

DRUG

lenalidomide

25 mg administrated by PO (with food)on Days 1-21

Trial Locations (2)

55905

Mayo Clinic Cancer Center, Rochester

85259-5499

Mayo Clinic Scottsdale, Scottsdale